Hyaluronic acid oligosaccharide-modified zeolitic imidazolate framework-8 nanoparticles loaded with oxaliplatin as a targeted drug-delivery system for colorectal cancer therapy

Nanomedicine (Lond). 2023 May;18(12):891-905. doi: 10.2217/nnm-2023-0096. Epub 2023 Jul 6.

Abstract

Aim: Exploring a nanoscale targeted drug-delivery system (DDS) for oxaliplatin (Oxa) to improve its therapeutic effect in colorectal cancer. Materials & methods: Nanoparticles were prepared using zeolitic imidazole framework-8 (ZIF-8) modified by hyaluronic acid oligosaccharide (oHA) as an Oxa carrier (oHA@ZIF-8@Oxa). After multiple characterizations, the therapeutic efficacy of the DDS was evaluated by cytotoxicity testing and a nude mouse tumor transplantation experiment in vivo. Results: The results of characterization showed the DDS was homogeneous in morphology and uniform in dispersion. The drug loading of Oxa was 11.82% and the encapsulation efficiency was 90.8%. The cytotoxicity test and in vivo experiments showed that oHA@ZIF-8@Oxa had a more significant anticolorectal cancer effect than free Oxa. Conclusion: This work offers a promising potential DDS for enhancing the anticolorectal cancer effect of Oxa.

Keywords: colorectal cancer therapy; drug-delivery system; hyaluronic acid oligosaccharide; metal–organic framework; oxaliplatin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Colorectal Neoplasms* / drug therapy
  • Drug Delivery Systems
  • Hyaluronic Acid / therapeutic use
  • Mice
  • Nanoparticles*
  • Oxaliplatin / therapeutic use
  • Zeolites*

Substances

  • Oxaliplatin
  • Hyaluronic Acid
  • Zeolites